Zoonoses

ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR RAPID EXTRACTION METHOD ON PROPRIETARY TEST SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2

Retrieved on: 
Tuesday, July 20, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Assay, COVID-19, DiaSorin, Curative

The rapid extraction method can be used on platforms including Enzos proprietary GENFLEX automated high-throughput platform, Qiagens QIAsymphony SP lower-throughput platform and Enzos manual workflow.

Key Points: 
  • The rapid extraction method can be used on platforms including Enzos proprietary GENFLEX automated high-throughput platform, Qiagens QIAsymphony SP lower-throughput platform and Enzos manual workflow.
  • The AMPIPROBE SARS-Cov-2 Test System includes three components: sample collection, AMPIXTRACT SARS-CoV-2 Extraction Kit for sample processing, and AMPIPROBE SARS-CoV-2 Assay Kit for detection and analysis.
  • We are positioned to support rapid scale up and advance the new solutions in molecular testing that can address major challenges like COVID.
  • The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

Retrieved on: 
Tuesday, July 20, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Coronaviridae, Zoonoses, Variants of SARS-CoV-2, Antiviral drugs, COVID-19 pandemic in Russia, Severe acute respiratory syndrome coronavirus 2, COVID-19, SARS-CoV-2 Delta variant, Immunome, Coronavir

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.
  • Furthermore, IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance.
  • IMM-BCP-01s ability to maintain neutralizing activity against emerging SARS-CoV-2 variants, including the Delta variant, potentially positions our drug candidate as a long-term solution to the changing threat posed by COVID-19.
  • Currently, the delta variant accounts for a majority of coronavirus cases in the United States.

Language Services Market Growth Analysis in IT Consulting & Other Services | Discover Company Insights in Technavio

Retrieved on: 
Tuesday, July 20, 2021
Articles, Philosophy, COVID-19, Occupational safety and health, Public health, Zoonoses, Optimism

Covers market data for 2020, 2021, till 2025

Key Points: 
  • Covers market data for 2020, 2021, till 2025
    Company profiling with detailed strategies, financials, and recent developments
    Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19.
  • Technavio's in-depth research has direct and indirect COVID-19 impacted market research reports.Register for a free trial today and gain instant access to 17,000+ market research reports.
  • Comprehensive details of factors that will challenge the growth of language services market, vendors

US COVID-19 Surveillance Needs an Urgent Boost, Says AHF

Retrieved on: 
Tuesday, July 20, 2021
Infectious diseases, Genetics, Public policy, Government, Healthcare reform, White House, Federal Government, Health, State, Local, Public policy, Other Policy Issues, Coronaviridae, Sarbecovirus, Zoonoses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Variant, SARS-CoV-2 Delta variant

New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.

Key Points: 
  • New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.
  • The most common strain of the virus is the highly infectious Delta variant, but the US is falling behind other developed countries in tracking and identifying new strains.
  • SARS-CoV-2 is highly prone to genetic variation as it replicates and spreads across different populations.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005833/en/

American Pharmacists Association Foundation, NOWDiagnostics Launch Nationwide In-Pharmacy Real-Time COVID-19 Antibody Testing with Spike Protein-Targeted, Rapid ADEXUSDx® Test

Retrieved on: 
Monday, July 19, 2021
Medical specialties, Medicine, Branches of biology, Virology, Immunology, Zoonoses, Glycoproteins, Clinical trials, Spike protein, COVID-19, Antibody, ZF2001

The ADEXUSDx COVID-19 antibody test detects antibodies that bind to the receptor binding domain (RBD) subunit of the S1 spike protein of the SARS-CoV-2 virus.

Key Points: 
  • The ADEXUSDx COVID-19 antibody test detects antibodies that bind to the receptor binding domain (RBD) subunit of the S1 spike protein of the SARS-CoV-2 virus.
  • The most protective antibodies develop against this portion of the spike protein S1 domain and are induced by vaccination.
  • The APhA Foundation is affiliated with the American Pharmacists Association, the oldest and largest national professional society of pharmacists in the United States established in 1852.
  • The ADEXUSDxCOVID-19 Test will be distributed by C19 Development, LLC, a wholly owned subsidiary of NOWDiagnostics.

Selva to Present Preclinical Data at ASV 2021 Demonstrating Prophylactic and Therapeutic Oral Dosing of SLV213 for COVID-19 Protected Lungs from SARS-CoV-2-Induced Damage

Retrieved on: 
Monday, July 19, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Hospitals, Clinical trials, Medicine, Medical specialties, Clinical medicine, Sarbecovirus, Antiviral drugs, COVID-19 drug development, Immune system, Zoonoses, Monoclonal antibody, Remdesivir, Severe acute respiratory syndrome coronavirus

Additional in vitro data show that SLV213 greatly enhances the efficacy of remdesivir and molnupiravir, two drugs that target the virus.

Key Points: 
  • Additional in vitro data show that SLV213 greatly enhances the efficacy of remdesivir and molnupiravir, two drugs that target the virus.
  • These data will be presented at the 40th Annual Meeting of the American Society of Virology (ASV) taking place virtually July 19-23.
  • Similar to monoclonal antibodies, SLV-213 inhibits the activation of the spike protein required for SARS-CoV-2 to infect a cell.
  • At ASV 2021, Selva will present data showing SLV213 protected lungs against damage when given as a therapeutic or a prophylactic in a nonhuman primate (NHP) model, compared to untreated controls.

Air-Clenz Systems Announces Technology Breakthrough That Captures, Isolates, and Cleans Exhaled Air in 10 Seconds and Within Two Feet of Individuals

Retrieved on: 
Monday, July 19, 2021
General Automotive, Health, Entertainment, Events, Concerts, Automotive, Commercial Building & Real Estate, Construction & Property, Air, Film & Motion Pictures, Transport, Building Systems, Infectious diseases, Public transport, Theatre, Articles, Zoonoses, Health, Occupational safety and health, Medical tests, Building engineering, Heating, ventilation, and air conditioning, Mechanical engineering, COVID-19, Virus

It cleans exhaled air and removes pathogens such as COVID-19 and the Delta variant within seconds, lowering the risk of contagion in enclosed spaces.

Key Points: 
  • It cleans exhaled air and removes pathogens such as COVID-19 and the Delta variant within seconds, lowering the risk of contagion in enclosed spaces.
  • View the full release here: https://www.businesswire.com/news/home/20210719005108/en/
    Air-Clenz Systems exhaled air cleaning technology is designed for most indoor, multi-seated venues, such as aircraft cabins.
  • It cleans exhaled air and removes pathogens such as COVID-19 and the Delta variant within seconds.
  • Many viruses -- including COVID-19 -- are primarily spread in aerosol form through the air and are generally not captured quickly by current HVAC systems.

EPA Approves Mass Transit Air Treatment Solution for Texas, Nevada, Pennsylvania and Maryland

Retrieved on: 
Monday, July 19, 2021
Zoonoses, Health, Animal diseases, Sarbecovirus, Biocides, Epidemiology, Infectious diseases, Antimicrobial, COVID-19, Severe acute respiratory syndrome, Virus

Administered through Luminator Technology Group 's (Luminator) Renew Air Treatment System , the solution provides continuous protection against SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • Administered through Luminator Technology Group 's (Luminator) Renew Air Treatment System , the solution provides continuous protection against SARS-CoV-2, the virus that causes COVID-19.
  • Approved use sites in Texas, Nevada, Pennsylvania and Maryland include intrastate transportation.For a complete listing of approved use sites, please visit EPA's website .
  • Luminator's Renew Air Treatment System dispenses the antimicrobial air treatment through a connected, technologically advanced system that measures and automatically adjusts the amount of Grignard Pure that is dispensed.
  • "We know now with certainty that the virus is airborne, and an antimicrobial air treatment solution is needed to combat the virus particles.

iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, July 15, 2021
Medical specialties, Zoonoses, Medicine, Branches of biology, Animal virology, Virology, Coronavirus, COVID-19, Severe acute respiratory syndrome coronavirus 2, Vaccine, Antigen

BRYAN, Texas, July 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (N protein) of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response.

Key Points: 
  • BRYAN, Texas, July 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (N protein) of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response.
  • Notably, the SARS-CoV-2 N protein shares substantial sequence conservation with the nucleocapsid of other coronaviruses.
  • The IBIO-202 immunization data are consistent with that, as a strong, cytotoxic, memory T-cell response was seen, rather than an inflammatory response.
  • iBio is developing proprietary products which include biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases.

Early Results of BetterLife Preclinical Study Showing AP-003 (rhIFNa2b) has Similar Potent Efficacy Against Different Variants of COVID-19

Retrieved on: 
Thursday, July 15, 2021
Antiviral drugs, Cytokines, Health sciences, Zoonoses, Interferon, Branches of biology, Medical specialties, COVID-19, Potency

Early data show potent and similar anti-viral activity against the COVID-19 Wuhan reference strain (EC50=0.51), Alpha (B.1.1.7, UK, EC50=1.26) and Beta (B.1.351, South Africa, EC50=0.25) variants.

Key Points: 
  • Early data show potent and similar anti-viral activity against the COVID-19 Wuhan reference strain (EC50=0.51), Alpha (B.1.1.7, UK, EC50=1.26) and Beta (B.1.351, South Africa, EC50=0.25) variants.
  • Further studies are ongoing to validate these early results and to test AP-003 activity against Gamma (Brazil), Delta (India) and Lambda (Peru) variants.
  • The rhIFN2b, a Type I interferon, is a naturally occurring protein integral to the bodys first line of anti-viral defenses.
  • The broad mechanism of action of interferon is such that our scientists hypothesized it could be equally effective against different variants.